Clinical trials for neuroregenerative therapies for spinal cord injury: what have we learnt so far?

Publikation

Clinical trials for neuroregenerative therapies for spinal cord injury: what have we learnt so far?

Wissenschaftlicher Artikel/Review - 26.05.2023

Wong Raymond, Hejrati Nader, Fehlings Michael G

Zitation

Wong R, Hejrati N, Fehlings M. Clinical trials for neuroregenerative therapies for spinal cord injury: what have we learnt so far?. Expert Rev Neurother 2023; 23:487-499.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Expert Rev Neurother 2023; 23

Veröffentlichungsdatum

26.05.2023

eISSN (Online)

1744-8360

Seiten

487-499

Kurzbeschreibung/Zielsetzung

There remains a lack of effective regenerative therapies to treat traumatic spinal cord injury (SCI). On a global level, patients living with SCI, their families, and the healthcare system are impacted by the extensive financial burden associated with the management of SCI. Clinical trials are crucial to assess the real-world efficacy of the different emerging neuroregenerative approaches that have shown promise in the pre-clinical stages of research.